| Immunology of COVID-19: current state of the science N Vabret, GJ Britton, C Gruber, S Hegde, J Kim, M Kuksin, R Levantovsky, ... Immunity 52 (6), 910-941, 2020 | 1696 | 2020 |
| Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage PK Mistry, J Liu, M Yang, T Nottoli, J McGrath, D Jain, K Zhang, J Keutzer, ... Proceedings of the National Academy of Sciences 107 (45), 19473-19478, 2010 | 274 | 2010 |
| The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals M Agrawal, OC Aroniadis, LJ Brandt, C Kelly, S Freeman, C Surawicz, ... Journal of clinical gastroenterology 50 (5), 403-407, 2016 | 197 | 2016 |
| Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists M Agrawal, EA Spencer, JF Colombel, RC Ungaro Gastroenterology 161 (1), 47-65, 2021 | 120 | 2021 |
| Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19 Z Izadi, EJ Brenner, SK Mahil, N Dand, ZZN Yiu, M Yates, RC Ungaro, ... JAMA network open 4 (10), e2129639-e2129639, 2021 | 109 | 2021 |
| European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation J Torres, M Chaparro, M Julsgaard, K Katsanos, Z Zelinkova, M Agrawal, ... Journal of Crohn's and Colitis 17 (1), 1-27, 2023 | 104 | 2023 |
| Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents J Axelrad, O Bernheim, JF Colombel, S Malerba, A Ananthakrishnan, ... Clinical gastroenterology and hepatology 14 (1), 58-64, 2016 | 102 | 2016 |
| Bone, inflammation, and inflammatory bowel disease M Agrawal, S Arora, J Li, R Rahmani, L Sun, AF Steinlauf, JI Mechanick, ... Current osteoporosis reports 9, 251-257, 2011 | 92 | 2011 |
| Fatigue in inflammatory bowel diseases: etiologies and management A Nocerino, A Nguyen, M Agrawal, A Mone, K Lakhani, A Swaminath Advances in therapy 37, 97-112, 2020 | 85 | 2020 |
| Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses M Agrawal, J Sabino, C Frias-Gomes, CM Hillenbrand, C Soudant, ... EClinicalMedicine 36, 2021 | 67 | 2021 |
| Multiomics to elucidate inflammatory bowel disease risk factors and pathways M Agrawal, KH Allin, F Petralia, JF Colombel, T Jess Nature Reviews Gastroenterology & Hepatology 19 (6), 399-409, 2022 | 65 | 2022 |
| Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry M Agrawal, EJ Brenner, X Zhang, I Modesto, J Woolcott, RC Ungaro, ... Inflammatory bowel diseases 27 (4), 585-589, 2021 | 62 | 2021 |
| JAK inhibitors safety in ulcerative colitis: practical implications M Agrawal, ES Kim, JF Colombel Journal of Crohn's and Colitis 14 (Supplement_2), S755-S760, 2020 | 62 | 2020 |
| Further evidence for direct pro-resorptive actions of FSH L Sun, Z Zhang, LL Zhu, Y Peng, X Liu, J Li, M Agrawal, LJ Robinson, ... Biochemical and biophysical research communications 394 (1), 6-11, 2010 | 61 | 2010 |
| Treat-to-target in inflammatory bowel diseases, what is the target and how do we treat? M Agrawal, JF Colombel Gastrointestinal Endoscopy Clinics 29 (3), 421-436, 2019 | 58 | 2019 |
| Impact of medications on COVID-19 outcomes in inflammatory bowel disease: analysis of more than 6000 patients from an international registry RC Ungaro, EJ Brenner, M Agrawal, X Zhang, MD Kappelman, ... Gastroenterology 162 (1), 316-319. e5, 2022 | 55 | 2022 |
| Longitudinal changes in fecal calprotectin levels among pregnant women with and without inflammatory bowel disease and their babies ES Kim, L Tarassishin, C Eisele, A Barre, N Nair, A Rendon, K Hawkins, ... Gastroenterology 160 (4), 1118-1130. e3, 2021 | 54 | 2021 |
| Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide … RC Ungaro, BN Limketkai, CB Jensen, KH Allin, M Agrawal, T Ullman, ... Gut 68 (6), 977-984, 2019 | 49 | 2019 |
| The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study M Agrawal, HS Christensen, M Bøgsted, JF Colombel, T Jess, KH Allin Gastroenterology 163 (6), 1547-1554. e5, 2022 | 40 | 2022 |
| Changing epidemiology of immune-mediated inflammatory diseases in immigrants: a systematic review of population-based studies M Agrawal, S Shah, A Patel, R Pinotti, JF Colombel, J Burisch Journal of autoimmunity 105, 102303, 2019 | 40 | 2019 |
